Skip to NavigationSkip to content

Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt

Published on 28/02/19 at 12:07pm

The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, but what could potentially be the biggest pharmaceutical industry merger of all time has been thrown into doubt thanks to a key BMS shareholder.

Top shareholder Wellington Management, which owns around 8% of BMS shares, has announced, in a rare move, that it does not support the prospective deal on the basis that it is a risky and expensive move. Celgene’s shares dropped by 8.5% following the news, but BMS shares rose 3% - the difference in share price between the two companies widened to almost 20%.

Activist hedge fund Starboard Value has been vocal in its opposition to the potential deal, canvassing its shareholders and filing a slate of nominees in a bid to put a stop to it. Analysts believe Wellington Management’s announcement could embolden this stance, and lead other shareholders to voice their disapproval for the deal.

However, BMS remained optimistic and determined: “We believe that we are acquiring Celgene at an attractive price, and that this transaction presents an important and unique opportunity to create sustainable value.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches